tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Digestive System Fistula D016154 1 associated lipids
Crigler-Najjar Syndrome D003414 1 associated lipids
Leukoplakia, Oral D007972 1 associated lipids
Peroneal Neuropathies D020427 1 associated lipids
Poxviridae Infections D011213 1 associated lipids
Kaposi Varicelliform Eruption D007617 1 associated lipids
Lacerations D022125 1 associated lipids
Megacolon, Toxic D008532 1 associated lipids
Tinea Capitis D014006 1 associated lipids
Polyomavirus Infections D027601 1 associated lipids
Lymphohistiocytosis, Hemophagocytic D051359 1 associated lipids
Rheumatoid Nodule D012218 1 associated lipids
Hernia, Ventral D006555 1 associated lipids
Hepatitis, Autoimmune D019693 1 associated lipids
Moyamoya Disease D009072 1 associated lipids
Apraxias D001072 1 associated lipids
Hypertensive Encephalopathy D020343 1 associated lipids
Hearing Loss, Bilateral D006312 1 associated lipids
Nocturia D053158 1 associated lipids
Echinostomiasis D004451 1 associated lipids
Multiple Endocrine Neoplasia Type 2a D018813 1 associated lipids
Latent Tuberculosis D055985 1 associated lipids
Nephritis, Hereditary D009394 1 associated lipids
Mastocytosis, Cutaneous D034701 1 associated lipids
Pancreatitis, Graft D055589 1 associated lipids
Hearing Loss, Sudden D003639 1 associated lipids
Rectal Diseases D012002 1 associated lipids
Citrullinemia D020159 1 associated lipids
Pulmonary Veno-Occlusive Disease D011668 1 associated lipids
Sweet Syndrome D016463 1 associated lipids
Optic Neuritis D009902 1 associated lipids
Granuloma Annulare D016460 1 associated lipids
Paraneoplastic Syndromes, Nervous System D020361 1 associated lipids
Intestinal Fistula D007412 1 associated lipids
Facial Nerve Injuries D020220 1 associated lipids
Intertrigo D007402 1 associated lipids
Miller Fisher Syndrome D019846 1 associated lipids
Cholangitis, Sclerosing D015209 1 associated lipids
Hepatic Insufficiency D048550 1 associated lipids
Lung Abscess D008169 1 associated lipids
Central Nervous System Viral Diseases D020805 1 associated lipids
Polyendocrinopathies, Autoimmune D016884 1 associated lipids
Leukoplakia D007971 1 associated lipids
Fasciitis, Necrotizing D019115 1 associated lipids
Mediastinal Emphysema D008478 1 associated lipids
Angiolymphoid Hyperplasia with Eosinophilia D000796 1 associated lipids
Eye Infections, Viral D015828 1 associated lipids
Dysplastic Nevus Syndrome D004416 1 associated lipids
Hypoplastic Left Heart Syndrome D018636 1 associated lipids
Mite Infestations D008924 1 associated lipids
Lymphocele D008210 1 associated lipids
Colitis, Collagenous D046729 1 associated lipids
Malacoplakia D008287 1 associated lipids
Myoclonic Cerebellar Dyssynergia D002527 1 associated lipids
Lichen Nitidus D017513 1 associated lipids
Lichenoid Eruptions D017512 1 associated lipids
Meningitis, Cryptococcal D016919 1 associated lipids
Oculomotor Nerve Diseases D015840 1 associated lipids
Cutis Laxa D003483 1 associated lipids
Invasive Pulmonary Aspergillosis D055744 1 associated lipids
Intestinal Volvulus D045822 1 associated lipids
Hand Injuries D006230 1 associated lipids
Beckwith-Wiedemann Syndrome D001506 1 associated lipids
Eye Diseases, Hereditary D015785 1 associated lipids
Feline Infectious Peritonitis D016766 1 associated lipids
End Stage Liver Disease D058625 1 associated lipids
Nocturnal Myoclonus Syndrome D020189 1 associated lipids
Uveomeningoencephalitic Syndrome D014607 1 associated lipids
Myelitis D009187 1 associated lipids
IgG Deficiency D017099 1 associated lipids
Deltaretrovirus Infections D006800 1 associated lipids
Hepatopulmonary Syndrome D020065 1 associated lipids
Herpes Labialis D006560 1 associated lipids
Polymyositis D017285 1 associated lipids
Scorpion Stings D065008 1 associated lipids
Rotavirus Infections D012400 1 associated lipids
Netherton Syndrome D056770 1 associated lipids
Pseudohypoaldosteronism D011546 1 associated lipids
Dendritic Cell Sarcoma, Interdigitating D054739 1 associated lipids
Intussusception D007443 1 associated lipids
Thrombotic Microangiopathies D057049 1 associated lipids
Autoimmune Diseases of the Nervous System D020274 1 associated lipids
Lupus Erythematosus, Discoid D008179 1 associated lipids
Lymphocytic Choriomeningitis D008216 1 associated lipids
Erythroplasia D004919 1 associated lipids
Hepatic Veno-Occlusive Disease D006504 1 associated lipids
West Nile Fever D014901 1 associated lipids
Hypoalbuminemia D034141 1 associated lipids
Arm Injuries D001134 1 associated lipids
Primary Graft Dysfunction D055031 1 associated lipids
Esophageal Perforation D004939 1 associated lipids
Epididymitis D004823 1 associated lipids
Pruritus Vulvae D011539 1 associated lipids
Central Serous Chorioretinopathy D056833 1 associated lipids
Feline Acquired Immunodeficiency Syndrome D016181 1 associated lipids
Budd-Chiari Syndrome D006502 1 associated lipids
AIDS-Associated Nephropathy D016263 1 associated lipids
Oral Ulcer D019226 1 associated lipids
Epidermolysis Bullosa Dystrophica D016108 1 associated lipids
Mutism D009155 1 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Christe W Neurological disorders in liver and kidney transplant recipients. 1994 Transplant. Proc. pmid:7527953
Bersztel A et al. Deoxyspergualin is synergistic with cyclosporin A, but not with FK506 in a rat heart allograft transplantation model. 1995 Transplant. Proc. pmid:8540095
Starzl TE FK 506 versus cyclosporine. 1993 Transplant. Proc. pmid:7679820
Fukuzaki T et al. Nonvascularized islet xenograft rejection in a mouse-to-rat combination where the vascularized heart is rapidly rejected. 1994 Transplant. Proc. pmid:7513472
Braun F et al. Primary tacrolimus immunosuppression in kidney recipients considered "higher immunological risk". 2000 Transplant. Proc. pmid:11119893
First International Congress on FK 506. August 21-24, 1991, Pittsburgh, PA. 1991 Transplant. Proc. pmid:1721253
García-Meseguer C et al. Efficacy and safety of basiliximab in pediatric renal transplantation. 2002 Transplant. Proc. pmid:11959206
Cadoff EM et al. Assay of FK 506 in plasma. 1990 Transplant. Proc. pmid:1689898
Venkataramanan R et al. Pharmacokinetics of FK 506: preclinical and clinical studies. 1990 Transplant. Proc. pmid:1689899
McDiarmid S et al. One hundred children treated with tacrolimus after primary orthotopic liver transplantation. 1998 Transplant. Proc. pmid:9636564
Wiesner RH Long-term comparison of tacrolimus versus cyclosporine in liver transplantation. The US FK Study Group. 1998 Transplant. Proc. pmid:9636565
Yao B et al. The incidence of posttransplantation diabetes mellitus during follow-up in kidney transplant recipients and relationship to Fok1 vitamin D receptor polymorphism. 2013 Jan-Feb Transplant. Proc. pmid:23375298
Rath T and Küpper M Comparison of inosine-monophosphate-dehydrogenase activity in patients with enteric-coated mycophenolate sodium or mycophenolate mofetil after renal transplantation. 2009 Jul-Aug Transplant. Proc. pmid:19715967
Fujikawa K et al. Effects of tacrolimus on rat thymic epithelial cells. 2000 Transplant. Proc. pmid:11120046
McCauley J et al. FK 506 in the management of nephrotic syndrome after renal transplantation. 1993 Transplant. Proc. pmid:7680154
Jordan ML et al. Tacrolimus-based immunosuppression in pediatric renal transplantation. 1999 Transplant. Proc. pmid:10576039
Farghali H et al. FK 506 modulates D-galactosamine-induced hepatitis in rats. 1991 Transplant. Proc. pmid:1721285
Andrews WS et al. Comparison of cyclosporine- vs tacrolimus-based immunosuppression in pediatric liver transplantation. 1996 Transplant. Proc. pmid:8623452
Iaria G et al. Prospective study of switch from cyclosporine to tacrolimus for fibroadenomas of the breast in kidney transplantation. 2010 Transplant. Proc. pmid:20534252
Kaminska D et al. Mycophenolate mofetil but not the type of calcineurin inhibitor (cyclosporine vs tacrolimus) influences the intragraft mRNA expression of cytokines in human kidney allograft biopsies by in situ RT-PCR analysis. 2005 Transplant. Proc. pmid:15848526
Manzia TM et al. Liver transplantation for hepatitis B and C virus-related cirrhosis: mid-term results. 2010 Transplant. Proc. pmid:20534261
Woodle ES A prospective, randomized, multicenter, double-blind study of early corticosteroid cessation versus long-term maintenance of corticosteroid therapy with tacrolimus and mycophenolate mofetil in primary renal transplant recipients: one year report. 2005 Transplant. Proc. pmid:15848538
Ciancio G et al. Use of intravenous tacrolimus to reverse vascular rejection in kidney and simultaneous kidney-pancreas transplantation. 1998 Transplant. Proc. pmid:9636624
Akiyama T et al. Mizoribine in combination therapy with tacrolimus for living donor renal transplantation: analysis of a nationwide study in Japan. 2005 Transplant. Proc. pmid:15848551
Bruce DS et al. Tacrolimus/mycophenolate provides superior immunosuppression relative to neoral/mycophenolate in synchronous pancreas-kidney transplantation. 1998 Transplant. Proc. pmid:9636625
Marzoa-Rivas R et al. Conversion of heart transplant patients from standard to sustained-release tacrolimus requires a dosage increase. 2010 Transplant. Proc. pmid:20970591
Kahan BD Forty years of publication of transplantation proceedings--the second decade: the cyclosporine revolution. 2009 Transplant. Proc. pmid:19545653
López-Montenegro Soria MA et al. Genetic polymorphisms and individualized tacrolimus dosing. 2010 Transplant. Proc. pmid:20970601
Andrés A et al. Extended-release tacrolimus therapy in de novo kidney transplant recipients: single-center experience. 2010 Transplant. Proc. pmid:20970602
Nowacka-Cieciura E et al. Late conversion to everolimus complicated with necrotizing glomerulonephritis in a renal allograft recipient: case report. 2009 Jan-Feb Transplant. Proc. pmid:19249576
Takada Y et al. Energy metabolism of hepatic allografts subjected to prolonged warm ischemia and pharmacologic modulation with FK506 and platelet activating factor antagonist. 1998 Transplant. Proc. pmid:9838621
Valdivia LA et al. Complement and target cells belong to the same species after liver xenografting: protection from hyperacute rejection. 1994 Transplant. Proc. pmid:7518123
Hayashi S et al. Synergistic effect of donor pretreatment using FK 506 in hamster-to-rat cardiac xenotransplantation. 1994 Transplant. Proc. pmid:7518126
Klintmalm GB et al. Rejection: FK 506 for rescue or maintenance. 1993 Transplant. Proc. pmid:7682356
Mor E et al. Weight gain and lipid profile changes in liver transplant recipients: long-term results of the American FK506 Multicenter Study. 1995 Transplant. Proc. pmid:7533363
Woodle ES et al. Recurrent rejection following FK 506 rescue therapy for acute hepatic allograft rejection. 1993 Transplant. Proc. pmid:7682358
Senninger N et al. Glucose metabolism following liver transplantation and immunosuppression with cyclosporine A or FK 506. 1995 Transplant. Proc. pmid:7533364
Jiang H et al. Combined immunosuppressive effect of FK 506 and other immunosuppressive agents on PHA- and CD3-stimulated human lymphocyte proliferation in vitro. 1991 Transplant. Proc. pmid:1721317
Yagihashi A et al. The effect of FK 506 on peripheral blood T-lymphocyte subsets in orthotopic liver transplant patients. 1991 Transplant. Proc. pmid:1721318
Schumacher G et al. Sirolimus inhibits growth of human hepatoma cells in contrast to tacrolimus which promotes cell growth. 2002 Transplant. Proc. pmid:12176410
Hohage H et al. Differential effects of cyclosporine and tacrolimus on mycophenolate pharmacokinetics in patients with impaired kidney function. 2005 Transplant. Proc. pmid:15919453
Saito S et al. The pattern of rejection and susceptibility to different kinds of immunosuppression after combined liver, duodenum, and pancreas transplantation in swine--immunosuppressive drugs versus ex vivo immunomodulation of the allograft. 1995 Transplant. Proc. pmid:7533420
Morel P et al. Liver retransplantation in adults: overall results and determinant factors affecting the outcome. 1991 Transplant. Proc. pmid:1721349
Borda B et al. Early histopathological changes in new-onset diabetes after kidney transplantation. Transplant. Proc. pmid:25131129
Porubsky M et al. Excellent outcomes can be achieved in young pancreas transplant alone recipients by addition of sirolimus to maintenance immunosuppression regimen. Transplant. Proc. pmid:25131074
Varo E et al. Incidence of cytomegalovirus infection and disease in orthotopic liver transplant patients immunosuppressed with cyclosporin versus tacrolimus. 2002 Transplant. Proc. pmid:12176488
Fukuhara N et al. Long-term outcome of tacrolimus in cadaveric kidney transplantation from non-heart-beating donors. 2002 Transplant. Proc. pmid:12176492
Emiroglu R et al. Tacrolimus-related neurologic and renal complications in liver transplantation: A single-center experience. 2006 Transplant. Proc. pmid:16549190
Takahashi N et al. Nitric oxide generation in renal allograft recipients. 1998 Transplant. Proc. pmid:9838306
Prates LC et al. Pain syndrome induced by calcineurin inhibitor and resolved by conversion to sirolimus in a child after kidney transplantation: a case report. 2012 Transplant. Proc. pmid:23026634
Yoshimura N et al. Effect of local immunosuppressive therapy with FK 506 on renal allograft survival in the mongrel dog. 1998 Transplant. Proc. pmid:9838372
Nishi K et al. The expression of intestinal CYP3A4 in the piglet model. 2004 Transplant. Proc. pmid:15050159
Sellers M et al. Incidence of late acute rejection and progression to chronic rejection in pediatric liver recipients. 1997 Feb-Mar Transplant. Proc. pmid:9123065
Di Benedetto F et al. University of Modena experience in HIV-positive patients undergoing liver transplantation. 2011 Transplant. Proc. pmid:21620066
Bonatti H et al. Liver transplantation for acute liver failure in children under 1 year of age. 1997 Feb-Mar Transplant. Proc. pmid:9123068
Costa A et al. Stimulatory effect of FK506 and erythromycin on pig intestinal motility. 1996 Transplant. Proc. pmid:8907957
Cicalese L et al. Effect of FK506 on the mucosal perfusion of the rat intestinal allograft. 1996 Transplant. Proc. pmid:8907959
Sun CK et al. Intensive care after orthotopic liver transplantation. 1994 Transplant. Proc. pmid:7520627
Sato K et al. Effectiveness of triple regimen immunosuppression in canine pancreatic allotransplantation. 1994 Transplant. Proc. pmid:7520628
Oishi M et al. Successful swine small bowel transplantation using FK506: effect on endotoxin translocation. 1994 Transplant. Proc. pmid:7520629
Song Z et al. Protective effect of FK-506 in pig-to-rat islet xenotransplantation is abrogated by prednisolone. 2000 Transplant. Proc. pmid:10936332
Yamada K et al. Short-term FK 506-induced morphological changes in rat kidneys. 1991 Transplant. Proc. pmid:1721381
Sola E et al. Low-dose and rapid steroid withdrawal in renal transplant patients treated with tacrolimus and mycophenolate mofetil. 2002 Transplant. Proc. pmid:12176537
Song Z et al. FK 506 prevents islet xenograft rejection: a study in the pig-to-rat model. 1999 Feb-Mar Transplant. Proc. pmid:10083437
Jambaljav L et al. Kidney transplantation achievements in Mongolia. 2010 Transplant. Proc. pmid:20430173
Iwamoto H et al. Early steroid withdrawal in adult kidney transplantation at a single center. 2012 Transplant. Proc. pmid:22310609
Mao PC et al. Trends in the use of immunosuppressive agents by outpatients after renal transplantation at a medical center in southern Taiwan. 2012 Transplant. Proc. pmid:22310611
Stratta RJ Simultaneous use of tacrolimus and mycophenolate mofetil in combined pancreas-kidney transplant recipients: a multi-center report. The FK/MMF Multi-Center Study Group. 1997 Feb-Mar Transplant. Proc. pmid:9123463
Fishbein T et al. Isolated intestinal transplantation in adults with nonreconstructible GI tracts. 2000 Transplant. Proc. pmid:10995925
Alessiani M et al. Correlations between functional changes and different grades of acute rejection in swine small bowel allografts. 2000 Transplant. Proc. pmid:10995933
Wang X et al. Intraportal FK 506 improves intrahepatic islet allograft survival. 1991 Transplant. Proc. pmid:1721412
Nishimura Y et al. Whole organ vascularized thymus allografting effectively modulates cardiac rejection. 1996 Transplant. Proc. pmid:8658660
Ohtsuka S et al. The effect of short-term FK 506 therapy on pancreas transplantation in rats. 1991 Transplant. Proc. pmid:1721413
Tanabe K et al. Diabetes mellitus after renal transplantation under FK 506 (tacrolimus) as primary immunosuppression. 1996 Transplant. Proc. pmid:8658670
McCarter JF et al. FK 506 protects brain tissue in animal models of stroke. 2001 Transplant. Proc. pmid:11377571
van Gelder T et al. ATP-binding cassette transporters and calcineurin inhibitors: potential clinical implications. 2001 Transplant. Proc. pmid:11377580
Fieguth HG et al. Tacrolimus for treatment of bronchiolitis obliterans syndrome after unilateral and bilateral lung transplantation. 2002 Transplant. Proc. pmid:12176613
Nayeri A et al. Acute Calcineurin Inhibitor Nephrotoxicity Secondary to Turmeric Intake: A Case Report. Transplant. Proc. pmid:28104136
Sicilia-Castro D et al. Reconstruction of a severe facial defect by allotransplantation in neurofibromatosis type 1: a case report. 2011 Transplant. Proc. pmid:21911174
Dudley CR Conversion at first rejection: a prospective trial comparing cyclosporine microemulsion with tacrolimus in renal transplant recipients. 2001 Feb-Mar Transplant. Proc. pmid:11267179
Kanatani T et al. Donor leukocytes combine with immunosuppressive drug therapy to prolong limb allograft survival. 2005 Transplant. Proc. pmid:15964421
Gnatta D et al. Use of tacrolimus and the development of posttransplant diabetes mellitus: a Brazilian single-center, observational study. 2010 Transplant. Proc. pmid:20304169
Ventura E et al. Calcineurin Inhibitor Determination in Whole Blood With the RXL Dimension Analyzer: A Useful Tool for Immunosuppressive Drug Monitoring. 2009 Transplant. Proc. pmid:19328963
Falkenstein K and Dunn S Tacrolimus to cyclosporine microemulsion formulation conversion in the pediatric liver transplant patient. 1998 Transplant. Proc. pmid:9723354
van der Laan LJ et al. Results of a two-center study comparing hepatic fibrosis progression in HCV-positive liver transplant patients receiving cyclosporine or tacrolimus. 2010 Transplant. Proc. pmid:21168740
Gruttadauria S et al. A safe immunosuppressive protocol in adult-to-adult living related liver transplantation. 2006 Transplant. Proc. pmid:16757278
Nanmoku K et al. Steroid Withdrawal Using Everolimus in ABO-Incompatible Kidney Transplant Recipients With Post-Transplant Diabetes Mellitus. 2018 Transplant. Proc. pmid:29631750
Wada H et al. Dose response to FK 506 in canine lung transplantation. 1991 Transplant. Proc. pmid:1721444
McMaster P and Buist L FK 506 in transplantation. 1993 Transplant. Proc. pmid:7689275
Pirenne J et al. Standard cyclosporine A-based versus completely steroid-free FK506-based immunosuppression after liver transplantation. 2001 Feb-Mar Transplant. Proc. pmid:11267396
Chang HK et al. Ten-Year Experience With Bowel Transplantation at Seoul St. Mary's Hospital. 2016 Transplant. Proc. pmid:27109981
Langrehr JM et al. A prospective, randomized trial with quadruple versus dual tacrolimus-based induction after liver transplantation. 2001 Feb-Mar Transplant. Proc. pmid:11267404
Baraldo M Meltdose Tacrolimus Pharmacokinetics. 2016 Transplant. Proc. pmid:27109969
Ribas Y et al. Lack of accommodation after long-term survival of hamster xenografts in rats. 1999 Transplant. Proc. pmid:10500752
Toki K et al. Histopathologic findings in routine biopsies of renal transplant allografts. 1999 Transplant. Proc. pmid:10500759
Müller V et al. Effect of mycophenolate mofetil on the in vivo infiltration of lymphocytes in the rat remnant kidney. 1998 Transplant. Proc. pmid:9636396
Silber RE et al. Comparison of the effect of FK 506 and alpha/beta-T-cell antibody R73 on transplant vascular sclerosis after heterotopic rat heart transplantation. 1998 Transplant. Proc. pmid:9636398
Wang M et al. Acute influence of FK506 on T-lymphocyte populations of peripheral blood and spleen in rats. 2007 Jan-Feb Transplant. Proc. pmid:17275526
Granot E et al. Monitoring of Epstein-Barr virus serology in children after liver transplant: lack of clinical correlation. 2000 Transplant. Proc. pmid:10856551
Friemann S et al. Improvement of nephrotoxicity, hypertension, and lipid metabolism after conversion of kidney transplant recipients from cyclosporine to tacrolimus. 1998 Transplant. Proc. pmid:9636504